Melatonin: From basic research to cancer treatment clinics

Unknown Vijayalaxmi, Charles R. Thomas, Russel J. Reiter, Terence S. Herman

Producción científica: Review articlerevisión exhaustiva

328 Citas (Scopus)


Melatonin, the chief secretary product of the pineal gland, is a direct free radical scavenger, an indirect antioxidant, as well as an important immuno-modulatory agent. In both in vitro and in vivo investigations, melatonin protected healthy cells from radiation-induced and chemotherapeutic drug-induced toxicity. Furthermore, several clinical studies have demonstrated the potential of melatonin, either alone or in combination with traditional therapy, to yield a favorable efficacy to toxicity ratio in the treatment of human cancers. This study reviews the literature from laboratory investigations that document the antioxidant and oncostatic actions of melatonin and summarizes the evidence regarding the potential use of melatonin in cancer treatment. This study also provides rationale for the design of larger translational research-based clinical trials.

Idioma originalEnglish (US)
Páginas (desde-hasta)2575-2601
Número de páginas27
PublicaciónJournal of Clinical Oncology
EstadoPublished - may 15 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Profundice en los temas de investigación de 'Melatonin: From basic research to cancer treatment clinics'. En conjunto forman una huella única.

Citar esto